A Japanese case of melanoma of unknown origin with a rare BRAFV600R mutation was successfully treated with BRAF/MEK inhibitors

被引：1

作者：

Kuriyama, Haruka ^{[1
]}

Kimura, Toshihiro ^{[1
]}

Mizuhashi, Satoru ^{[1
]}

Nishimura, Yuki ^{[1
]}

Kanemaru, Hisashi ^{[1
]}

Kajihara, Ikko ^{[1
]}

Makino, Katsunari ^{[1
]}

Aoi, Jun ^{[1
]}

Matsui, Hirotaka ^{[2
]}

Fukushima, Satoshi ^{[1
]}

机构：

[1] Kumamoto Univ, Dept Dermatol & Plast Surg, Fac Life Sci, Kumamoto, Japan

[2] Kumamoto Univ, Grad Sch Med Sci, Dept Mol Lab Med, Kumamoto, Japan

来源：

DRUG DISCOVERIES AND THERAPEUTICS | 2022年 / 16卷 / 05期

关键词：

BRAF; V600R; melanoma; FoundationOne CDx;

D O I：

10.5582/ddt.2022.01072

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Combination therapy with BRAF and MEK inhibitors ( BRAF/ MEKi) has shown significantly prolonged progression-free survival (PFS) and overall survival (OS) for BRAF mutated melanoma. Over 90% of the activating mutations are BRAFV(600E) or BRAF(V600K) changes. There are no reports of BRAFV600R in Japanese patients with melanoma. The third most common BRAF mutation is BRAF(V600R). In this case, we detected the BRAF(V600R) mutation with FoundationOne CDx in a Japanese patient with melanoma.. The patient was treated with BRAF/MEKi and maintained stable disease status for 1 year.

引用

页码：256 / 257

页数：2

共 5 条

[1] Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial [J].

Dummer, Reinhard ;

Ascierto, Paolo A. ;

Gogas, Helen J. ;

Arance, Ana ;

Mandala, Mario ;

Liszkay, Gabriella ;

Garbe, Claus ;

Schadendorf, Dirk ;

Krajsova, Ivana ;

Gutzmer, Ralf ;

Chiarion-Sileni, Vanna ;

Dutriaux, Caroline ;

de Groot, Jan Willem B. ;

Yamazaki, Naoya ;

Loquai, Carmen ;

Moutouh-de Parseval, Laure A. ;

Pickard, Michael D. ;

Sandor, Victor ;

Robert, Caroline ;

Flaherty, Keith T. .

LANCET ONCOLOGY, 2018, 19 (05) :603-615

[2]

Houben Roland, 2004, J Carcinog, V3, P6, DOI 10.1186/1477-3163-3-6

[3] BRAF inhibitor activity in V600R metastatic melanoma - Response [J].

Klein, Oliver ;

Clements, Arthur ;

Menzies, Alexander M. ;

O'Toole, Sandra ;

Kefford, Richard F. ;

Long, Georgina V. .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (07) :1797-1798

[4] Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients [J].

Sakaizawa, Kaori ;

Ashida, Atsuko ;

Uchiyama, Aya ;

Ito, Takamichi ;

Fujisawa, Yasuhiro ;

Ogata, Dai ;

Matsushita, Shigeto ;

Fujii, Kazuyasu ;

Fukushima, Satoshi ;

Shibayama, Yoshitsugu ;

Hatta, Naohito ;

Takenouchi, Tatsuya ;

Uehara, Jiro ;

Okuyama, Ryuhei ;

Yamazaki, Naoya ;

Uhara, Hisashi .

JOURNAL OF DERMATOLOGICAL SCIENCE, 2015, 80 (01) :33-37

[5] The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma [J].

Trudel, Stephanie ;

Odolczyk, Norbert ;

Dremaux, Julie ;

Toffin, Jerome ;

Regnier, Aline ;

Sevestre, Henri ;

Zielenkiewicz, Piotr ;

Arnault, Jean-Philippe ;

Gubler, Brigitte .

BMC CANCER, 2014, 14

← 1 →